Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis

201962 citationsJournal Articlebronze Open Access

Authors

Erica D. Dommasch · Brigham and Women's Hospital

Seoyoung C. Kim · Brigham and Women's Hospital

Moa P. Lee · University of North Carolina at Chapel Hill

Abstract

Among patients with psoriasis treated with systemic medications in 2 large US claims databases, new users of apremilast, etanercept, and ustekinumab had a decreased rate of serious infection compared with methotrexate.

Topics & Keywords

Psoriasis: Treatment and Pathogenesis Health Systems, Economic Evaluations, Quality of Life Pharmaceutical studies and practices

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA Dermatology

Volume 155, Issue 10, pp. 1142-1142

DOI: 10.1001/jamadermatol.2019.1121

Field-Weighted Citation Impact: 3.76